Technical Analysis for CRDL - Cardiol Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.96% | |
| Below Lower BB | Weakness | 0.96% | |
| Down 3 Days in a Row | Weakness | 0.96% | |
| Down 4 Days in a Row | Weakness | 0.96% | |
| Down 5 Days in a Row | Weakness | 0.96% | |
| Lower Bollinger Band Touch | Weakness | 0.96% | |
| Oversold Stochastic | Weakness | 0.96% | |
| Lower Bollinger Band Walk | Weakness | -4.55% | |
| Below Lower BB | Weakness | -4.55% | |
| Down 3 Days in a Row | Weakness | -4.55% |
| Alert | Time |
|---|---|
| Possible NR7 | about 2 hours ago |
| 2x Volume Pace | about 6 hours ago |
| 1.5x Volume Pace | about 6 hours ago |
| Down 3% | about 6 hours ago |
| Down 2 % | about 6 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/12/2024
Cardiol Therapeutics Inc. Description
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Disease Clinical Research Heart Failure Orphan Drug Heart Disease Cannabidiol
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.12 |
| 52 Week Low | 0.7925 |
| Average Volume | 520,172 |
| 200-Day Moving Average | 1.96 |
| 50-Day Moving Average | 1.97 |
| 20-Day Moving Average | 1.86 |
| 10-Day Moving Average | 1.85 |
| Average True Range | 0.14 |
| RSI (14) | 28.57 |
| ADX | 17.57 |
| +DI | 17.21 |
| -DI | 25.69 |
| Chandelier Exit (Long, 3 ATRs) | 1.83 |
| Chandelier Exit (Short, 3 ATRs) | 1.95 |
| Upper Bollinger Bands | 2.08 |
| Lower Bollinger Band | 1.64 |
| Percent B (%b) | -0.19 |
| BandWidth | 23.66 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.03 |
| MACD Histogram | -0.0316 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.75 | ||||
| Resistance 3 (R3) | 1.76 | 1.71 | 1.72 | ||
| Resistance 2 (R2) | 1.71 | 1.67 | 1.71 | 1.71 | |
| Resistance 1 (R1) | 1.64 | 1.64 | 1.61 | 1.62 | 1.70 |
| Pivot Point | 1.59 | 1.59 | 1.58 | 1.58 | 1.59 |
| Support 1 (S1) | 1.51 | 1.54 | 1.49 | 1.50 | 1.42 |
| Support 2 (S2) | 1.46 | 1.51 | 1.46 | 1.41 | |
| Support 3 (S3) | 1.39 | 1.46 | 1.40 | ||
| Support 4 (S4) | 1.37 |
